This report represents, to the best of our knowledge, the first description of a dramatic—albeit brief—clinical and radiographic tumor response to combined selective inhibition of ROS1 and MET using lorlatinib plus capmatinib in the setting of acquired resistance to sequential ROS1 inhibitor therapy (crizotinib followed by lorlatinib) due to MET amplification. Here, ROS1 is linked to neoplasm.